Entrada Therapeutics, Inc. (TRDA) research
Entrada Therapeutics, Inc.- Sector
- Biotechnology
- Last price
- $5.38
- As of
Entrada Therapeutics, Inc. (TRDA): 6 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-05.
As of . Source: SEC EDGAR filings for TRDA. Method and limitations.
Share the TRDA intelligence card
See the full TRDA dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for TRDA on one page. Preview it with sample data, then open it live with a free account.
Preview the TRDA dossierActive signals for TRDA
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +120% to TRDA (2026Q2)
- highINSTITUTIONAL_EXIT
D. E. Shaw & Co., Inc. cut 59% of TRDA (2026Q2)
- mediumEARNINGS_BEAT
Q2-2026: Beat consensus by 5.7%, EPS $-1.01 vs $-1.071 estimate
- mediumEARNINGS_BEAT
Q4-2025: Beat consensus by 19.9% - EPS $-0.94 vs $-1.173 estimate
- mediumEARNINGS_MISS
Q2-2025: Missed consensus by 20.3% - EPS $-1.04 vs $-0.8645 estimate
FREE, NO ACCOUNT
Every signal on TRDA, as it fires
You are seeing 5 of 8 signals recorded on TRDA since 2026-05-24.
The five above landed across 4 days. The other 3 were recorded on those same days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in TRDA (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| MILLENNIUM MANAGEMENT LLCCUSIP 29384C108 · 2026Q2 | $5.6M | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 29384C108 · 2026Q2 | $2.9M | 0.00% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 29384C108 · 2026Q2 | $1.4M | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 29384C108 · 2026Q2 | $342K | 0.00% | , |
| D. E. Shaw & Co., Inc.CUSIP 29384C108 · 2026Q2 | $238K | 0.00% | , |
| Point72 Asset Management, L.P.CUSIP 29384C108 · 2026Q2 | $210K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, TRDA
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
TRDA against its peers
TRDA's operating margin of -621.1% ranks in the 29th percentile of 18 Biotechnology sub-industry peers, fiscal period ending 2025-12-31.
| Metric | TRDA | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 25.4M USD | 19.4M USD | 58 | 17 |
| Operating margin | -621.1% | -236.6% | 29 | 18 |
| Net margin | -565.5% | -149.5% | 18 | 18 |
| Return on equity | -47.0% | -43.7% | 50 | 22 |
Peers (24): WHWK, XGN, ANTX, ELDN, ALEC, PLX, CGEN, NAUT, CUE, NAGE, RNAC, KROS, MGNX, NGEN, ADAG, LYEL, PRQR, IPHA, SION, LCTX, ACOG, ORMP, SLGL, NKTX. Left out: VRXA (no annual filing). Fiscal period ending 2025-12-31. Every figure is one full fiscal year read from one annual filing (TRDA: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more TRDA signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to TRDAand get the insider, 13F, options, and confluence read in one view.